IMR Press / FBL / Volume 22 / Issue 10 / DOI: 10.2741/4568

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Theranostic biomarkers in hypertrophic cardiomyopathy: insights in a long road ahead

Show Less
1 Department of Cardiovascular Diseases, Vita Salute University and San Raffaele Hospital, Milan, Italy
2 Prevention and Rehabilitation Unit, Fondazione Don Gnocchi, Parma, Italy
3 Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Milan Italy

Academic Editors: Isabella Castiglioni, Gloria Bertoli, Claudia Cava

Front. Biosci. (Landmark Ed) 2017, 22(10), 1724–1749;
Published: 1 March 2017
(This article belongs to the Special Issue Frontiers in biomarker for theranostics)

The study of biomarkers and their related signalling pathways has allowed the development of new therapeutic strategies in a range of disorders. However, in hypertrophic cardiomyopathy (HCM), which is the most common hereditary cardiac disease, there are many potential biomarkers described, but their specificity and applicability for HCM remains an open field. The aim of the present review is to provide an overview of molecules that could give some insight into the pathophysiologic mechanisms underlying HCM, especially to those with “theranostic” - a combination of diagnostics and therapy - potential. The clinical and pre-clinical state of the art and theranostic perspectives of this topic is discussed in the present review. The better understanding of this subject would provide an algorithm, to optimize the integration of diagnosis, prognostics and therapeutics findings in HCM, leading to a tailored approach for this pathology.

Hypertrophic Cardiomyopathy
Primary Cardiomyopathy
Back to top